The relationship between prostate cancer treatment efficacy, survival and race | Robert Dreicer

(3:17)

Dr. Robert Dreicer Discusses Sequencing MDV3100 and Abiraterone

(1:2)

Dr. Robert Dreicer on Drug Development Challenges in Prostate Cancer

(53)

Dr. Robert Dreicer on Sequencing Therapies in Prostate Cancer

(1:18)

Dr. Robert Dreicer on an Alternate Sunitinib Schedule in Metastatic Renal Cell Carcinoma

(40)

Dr. Robert Dreicer on Utilizing New Prostate Cancer Therapies

(1:1econd)

Dr. Robert Dreicer Discusses Using Abiraterone Acetate

(1:14)

Dr. Robert Dreicer on Potential Combinations in Prostate Cancer

(52)

Robert Dreicer, MD, describes the results of the Javelin-100 Bladder cancer trial

(2:5)

Dr. Dreicer on the Treatment of Bladder Cancer

(56)

Dr. Dreicer on Ongoing Trials in Prostate Cancer

(57)

Dr. Dreicer on Trial Endpoints in Prostate Cancer

(49)

Dr. Dreicer on Combination Trials With Radium-223 in mCRPC

(58)

How Clinical Trials Improve Cancer Care

(9:9)

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

(1:50)

Dr. Dreicer on Combinations and Sequencing Agents With Immunotherapies in Prostate Cancer

(53)

Dr. Dreicer Comments on Trial Endpoints in Prostate Cancer

(1:1econd)

Robert Dreicer, MD, provides results presented concerning PSMA-linked 177Lutethium regarding mCRPC

(2:9)

Robert Dreicer, MD, updates us on the role of cabazitaxel from the CARD study

(2:)

Dr. Dreicer on the Need to Diagnose and Treat Efficiently

(52)